Table 4 Descriptive correlation of HLA-G and HLA-F isoforms with low and high levels of expression and pathological complete response status in the subtypes.
From: HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment
HER2+ (n = 28) | Luminal B-like (n = 49) | Triple-negative (n = 38) | ||||
|---|---|---|---|---|---|---|
No pCR | pCR | No pCR | pCR | No pCR | pCR | |
Low HLA-F1 | 5 (36%) | 9 (64%) | 19 (79%) | 5 (21%) | 10 (53%) | 9 (47%) |
High HLA-F1 | 5 (36%) | 9 (64%) | 22 (88%) | 3 (12%) | 9 (47%) | 10 (53%) |
Low HLA-F3 | 5 (33%) | 10 (67%) | 21 (84%) | 4 (16%) | 11 (65%) | 6 (35%) |
High HLA-F3 | 5 (42%) | 7 (58%) | 20 (83%) | 4 (17%) | 8 (38%) | 13 (62%) |
Low HLA-G1 | 6 (46%) | 7 (54%) | 19 (86%) | 3 (16%) | 9 (45%) | 11 (55%) |
High HLA-G1 | 4 (29%) | 10 (71%) | 20 (83%) | 4 (17%) | 8 (50%) | 8 (50%) |
Low HLA-G2 | 7 (32%) | 15 (68%) | 33 (85%) | 6 (15%) | 17 (55%) | 14 (45%) |
High HLA-G2 | 3 (50%) | 3 (50%) | 8 (80%) | 2 (20%) | 2 (29%) | 5 (71%) |
Low HLA-G3 | 6 (35%) | 11 (65%) | 21 (88%) | 3 (12%) | 7 (47%) | 8 (53%) |
High HLA-G3 | 4 (36%) | 7 (64%) | 18 (78%) | 5 (22%) | 11 (50%) | 11 (50%) |
Low HLA-G5 | 4 (36%) | 7 (64%) | 20 (83%) | 4 (17%) | 12 (57%) | 9 (43%) |
High HLA-G5 | 6 (35%) | 11 (65%) | 18 (82%) | 4 (18%) | 7 (41%) | 10 (59%) |
Low HLA-G6 | 2 (14%) | 12 (86%) | 21 (88%) | 3 (12%) | 13 (68%) | 6 (32%) |
High HLA-G6 | 7 (54%) | 6 (46%) | 20 (80%) | 5 (20%) | 6 (32%) | 13 (68%) |
